AbbVie Denies Revolution Medicines Talks Amid Market Turbulence
AbbVie's abrupt denial of acquisition talks with Revolution Medicines sent shockwaves through biotech and crypto markets alike. The pharmaceutical giant's statement contradicted a Wall Street Journal report suggesting advanced discussions for the $20 billion cancer-drug developer. Revolution Medicines' shares plunged 11.5% post-denial, erasing a 30% intraday surge fueled by acquisition speculation.
The news rippled into crypto markets as traders weighed implications for biotech-linked tokens. Projects like AGI (SingularityNET) and FET (Fetch.ai), which intersect AI and drug discovery, saw muted reactions—a sign crypto investors remain focused on macro liquidity trends rather than sector-specific pharma developments.
AbbVie's simultaneous profit forecast cut—slashing 2025 guidance by 7% due to a $1.3B Q4 charge—further dampened risk appetite. The MOVE echoes crypto's sensitivity to corporate earnings disappointments, as seen when Tesla's Q1 miss triggered parallel selloffs in BTC and biotech tokens last April.